BEND, Ore.--(BUSINESS WIRE)--
Independent testing laboratory in final phase to perform state compliance testing
EVIO Inc. (“EVIO†or the “Companyâ€), (EVIO), a leading provider of cannabis testing and research for the regulated cannabis industry in North America announced today that it received a provisional license from Massachusetts Cannabis Control Commission (CCC) to operate as an independent testing laboratory. The license moves the organization into the final phase of being cleared to commence testing cannabis under the Commonwealth’s Adult Use of Marijuana Program. EVIO Labs in Framingham will be one of only four Massachusetts laboratories approved to perform mandated testing to measure product potency and to verify that cannabis is clean from contaminants including pesticides, heavy metals, including lead and mercury, and microbes, including e. coli and salmonella.
“We are excited to offer full service testing for the state’s exploding adult-use market. The first two recreational cannabis dispensaries opened on November 20, 2018 and according to the CCC, sales exceeded $2 million in the first five days. Additional dispensaries are awaiting final license approval to enter this $1.2B cannabis market. We have already established relationships with a majority of the growers and producers across the Commonwealth and we look forward to serving them,†said Lori Glauser, COO of EVIO. “As more consumers try cannabis including CBD products, it is vitally important that the product is safe, and the product labels are accurate.â€
The provisional license permits EVIO Labs to complete the relocation to its new Framingham facility, reoptimize the equipment to support EVIO’s ISO accredited methods and complete preparations for final inspection. We are forecasting this process will be complete within the next 30 to 45 days.
About EVIO Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company’s EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply. The Company’s EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.
For more information, visit www.eviolabs.com.
Safe Harbor Statement
Any statements in this press release that are not statements of historical fact maybe considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005236/en/